AKBA Akebia Therapeutics Inc.

3.05
-0.12  -4%
Previous Close 3.17
Open 3.14
52 Week Low 2.09
52 Week High 13.71
Market Cap $440,843,627
Shares 144,538,894
Float 125,698,317
Enterprise Value $277,007,626
Volume 4,205,761
Av. Daily Volume 6,002,087
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
NDA Filing
NDA Filing
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
NDA Filing
NDA Filing
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Vadadustat
COVID-19
Phase 3
Phase 3
Phase 3 initiation announced July 14, 2020.
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients
Approved
Approved
sNDA FDA Approval announced November 7, 2017.
Auryxia
Hyperphosphatemia
Approved
Approved
Approved Sept 5, 2014.

Latest News

  1. CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference, which takes place virtually January 11 – 14, 2021. 

    CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference, which takes place virtually January 11 – 14, 2021. 

    AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)">

    The recorded presentation will be available on the Investors section of the Company's website at https://ir.akebia.com beginning Monday, January 11.

    About Akebia Therapeutics

    Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

    Akebia Therapeutics Contact

    Kristen K. Sheppard, Esq.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-hc-wainwright-bioconnect-2021-conference-301201492.html

    SOURCE Akebia Therapeutics

    View Full Article Hide Full Article
  2. CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 89,000 shares of Akebia's common stock on December 31, 2020, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

    CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 89,000 shares of Akebia's common stock on December 31, 2020, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

    AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)">

    The options have an exercise price of $2.80 per share, which is equal to the closing price of Akebia's common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of the company's Inducement Award Program and a stock option agreement covering the grant.

    About Akebia Therapeutics

    Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

    Akebia Therapeutics Contact

    Kristen K. Sheppard, Esq.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301201326.html

    SOURCE Akebia Therapeutics

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., Jan. 4, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, at 2:50 p.m. EST.

    CAMBRIDGE, Mass., Jan. 4, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, at 2:50 p.m. EST.

    AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)">

    A live webcast and replay of Akebia's presentation and associated Q&A will be available on the Investors section of the Company's website at https://ir.akebia.com.

    About Akebia Therapeutics

    Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

    Akebia Therapeutics Contact

    Kristen K. Sheppard, Esq.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-39th-annual-jp-morgan-healthcare-conference-301199899.html

    SOURCE Akebia Therapeutics

    View Full Article Hide Full Article
  4. CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community. The upcoming virtual panel, scheduled for Wednesday, December 16, 2020 at 7:30 p.m. EST, will feature a discussion among kidney care professionals who will share their insights and experiences managing hyperphosphatemia in people with chronic kidney disease (CKD) on dialysis. AkebiaShares aims to bring together kidney professionals to share information and best practices on topics related to providing care to people with CKD.

    CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community. The upcoming virtual panel, scheduled for Wednesday, December 16, 2020 at 7:30 p.m. EST, will feature a discussion among kidney care professionals who will share their insights and experiences managing hyperphosphatemia in people with chronic kidney disease (CKD) on dialysis. AkebiaShares aims to bring together kidney professionals to share information and best practices on topics related to providing care to people with CKD.

    AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)">

    Hyperphosphatemia is a condition in which a person's phosphorus levels are too high, potentially causing serious damage to the body. It is a primary hallmark of CKD, particularly in people with end-stage renal disease and on dialysis. The panelists will share information on hyperphosphatemia in people on dialysis, and discuss management including the value of a multidisciplinary care team, ongoing patient engagement and monitoring via telehealth, and the use of phosphate binders as a treatment option.

    To register for the complimentary event visit: http://dwa.adobeconnect.com/endruu01ne5s/event/registration.html?campaign-id=akebia5.

    The discussion will be moderated by German Hernandez, M.D., nephrologist at El Paso Kidney Specialists and Karen Robertson, DNP, ANP, nurse practitioner at Carolina Nephrology. Joining the discussion will be Beth Morlang, RD, renal dietitian at Central Florida Kidney Centers, Inc.   

    Akebia markets AURYXIA® (ferric citrate), a phosphate binder that contains iron, which is approved by the U.S. Food and Drug Administration (FDA) and marketed for two indications in the U.S.: the control of serum phosphorus levels in adult patients with CKD on dialysis (the Hyperphosphatemia Indication), and the treatment of iron deficiency anemia (IDA) in adult patients with CKD not on dialysis (the IDA Indication).

    About Akebia Therapeutics

    Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

    About Auryxia® (ferric citrate) Tablets

    Auryxia (ferric citrate) was approved by the FDA on September 5, 2014 for the control of serum phosphorus levels in adult patients with CKD on dialysis and approved by the FDA on November 6, 2017 for the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. For more information about Auryxia and the U.S. full prescribing information, please visit www.auryxia.com.

    IMPORTANT SAFETY INFORMATION CONTRAINDICATION

    AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

    WARNINGS AND PRECAUTIONS

    • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
    • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

    ADVERSE REACTIONS

    The most common adverse reactions reported with AURYXIA in clinical trials were:

    • Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)
    • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)

    SPECIFIC POPULATIONS

    • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

    To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

    Please see full Prescribing Information.

    Akebia Therapeutics Contact

    Kristen K. Sheppard, Esq

     

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/akebiashares-program-current-approaches-for-managing-hyperphosphatemia-and-caring-for-patients-via-telehealth-301188803.html

    SOURCE Akebia Therapeutics

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on November 30, 2020, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

    CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on November 30, 2020, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

    AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)">

    The options have an exercise price of $3.31 per share, which is equal to the closing price of Akebia's common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of the company's Inducement Award Program and a stock option agreement covering the grant.

    About Akebia Therapeutics

    Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

    Akebia Therapeutics Contact

    Kristen K. Sheppard, Esq.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301183958.html

    SOURCE Akebia Therapeutics

    View Full Article Hide Full Article
View All Akebia Therapeutics Inc. News